Henry Schein stock, healthcare distribution

Raised guidance supports Henry Schein stock after Q2 beat

Published on 09/29/2026 at 06:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Henry Schein stock was priced at USD 85.99 on September 28, 2026, while Q2 sales grew 6.7 percent to USD 3.5 billion. Adjusted EPS rose 15.5 percent to USD 1.27.

Moderne Zahnarztpraxis mit Behandlungsstuhl und medizinischen Instrumenten, Henry Schein Sektor
Henry Schein US42548G1040 versorgt Zahnarztpraxen weltweit mit hochwertigen medizinischen Produkten und Dentalgeräten, Illustration mit AI erstellt.

Raised 2026 guidance gives Henry Schein stock a clear earnings anchor after the company reported second-quarter sales of USD 3.5 billion and a share price of USD 85.99 on Nasdaq on September 28, 2026. The latest corporate update also expanded financing capacity, putting capital allocation alongside operating growth.

Credit capacity reaches USD 1.25 billion

According to The Globe and Mail on September 21, 2026, Henry Schein increased its revolving credit commitments from USD 1.0 billion to USD 1.25 billion and extended the facility termination date to September 19, 2031. The agreement permits working capital, capital expenditures, share repurchases, refinancing and potential acquisitions, although the filing described additional capacity rather than cash raised.

The financing change matters because it widens strategic flexibility while the company is funding value creation initiatives. It also gives investors a concrete balance-sheet marker to compare with the earnings-led growth story.

Q2 earnings beat expectations

In the second quarter ended June 27, 2026, Henry Schein delivered USD 3.5 billion in sales, up 6.7 percent from the prior-year quarter, according to The Globe and Mail. Non-GAAP diluted EPS reached USD 1.27, rising 15.5 percent from USD 1.10 in the second quarter of 2025, while GAAP diluted EPS was USD 0.82 versus USD 0.70.

Management raised full-year 2026 sales-growth guidance to 4.5 percent to 5.5 percent from 3 percent to 5 percent. Non-GAAP diluted EPS guidance moved to USD 5.29 to USD 5.39 from USD 5.23 to USD 5.37, making the guidance revision more precise than a simple revenue expansion story.

Analyst target remains above the stock

MarketBeat reported on September 28, 2026, that 15 analysts held a Moderate Buy consensus, with an average 12-month price target of USD 92.93. That target stands 8.07 percent above the September 28 price of USD 85.99, while recent targets ranged from USD 95.00 to USD 112.00.

Stock stays below its yearly high

Henry Schein stock was priced at USD 85.99 on Nasdaq on September 28, 2026, with a market capitalization of USD 9.6 billion and volume of 959,380 shares. The 52-week range was USD 61.95 to USD 92.18, leaving the stock 6.72 percent below its yearly high.

Henry Schein stock snapshot

  • Company: Henry Schein, Inc.
  • Ticker: HSIC
  • Trading venue: Nasdaq
  • Price (as of September 28, 2026): USD 85.99
  • Market capitalization: USD 9.6 billion (as of September 28, 2026)
  • 52-week range: USD 61.95-92.18 (as of September 28, 2026)
  • Sector / Industry: Health Care / Medical Devices
  • Index membership: S&P 500

Disclaimer...

en | boerse | 70196142 |